Issue link: https://nebusinessmedia.uberflip.com/i/1305031
n e w h a v e n b i z . c o m | N o v e m b e r / D e c e m b e r 2 0 2 0 | n e w h a v e n B I Z 21 T H E L I S T Largest Bioscience/Biotechnology Companies, South Central Connecticut Ranked by number of employees Largest Bioscience/Biotechnology Companies South Central Connecticut (Ranked by number of employees) Rank Company No. CT employees/ Headquarters Focus Ownership/ Ticker Chief executive/ Year founded 1 Medtronic Inc. 60 Middletown Ave. North Haven 06473 203-492-5000; www.medtronic.com 1,500 Dublin, Ireland Development, manufacturing and sales of surgical staplers Public NYSE: MDT Geoffrey S. Martha CEO 1949 2 Alexion Pharmaceuticals Inc. (a) 100 College St. New Haven 06510 475-230-2596; alexion.com 500 Boston, Mass. Severe and life-threatening rare disorders Public NASDAQ: ALXN Ludwig N. Hantson CEO 1992 2 PerkinElmer Inc. 710 Bridgeport Ave. Shelton 06484 (b) 203-925-4600; www.perkinelmer.com 500 (c) Waltham, Mass. Detection, imaging, informatics, software and services innovating for a healthier world Public NYSE: PKI Prahlad Singh CEO (d) 1937 4 Sema4 1 Commercial St. Branford 06405 800-298-6470; sema4.com 300 Stamford Patient-centered health intelligence for reproductive health and oncology Private Eric Schadt Founder & CEO 2017 5 Arvinas Inc. 5 Science Park, 395 Winchester Ave. New Haven 06511 203-535-1456; www.arvinas.com 132 New Haven Development of therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare disease Public NASDAQ: ARVN John Houston President & CEO 2013 6 Biohaven Pharmaceutical Holding Co. LTD 215 Church St. New Haven 06510 203-404-0410; biohavenpharma.com 100 New Haven Neuroscience Public NYSE: BHVN Vlad Coric CEO 2013 7 Sanofi Pasteur 1000 Research Parkway Meriden 06450 203-427-2403; www.sanofi.com 71 Swiftwater, Pa. Vaccine development and protein production Public NASDAQ: SNY (e) Paul Hudson CEO 1994 8 Ce3 Inc. 6 Post Office Square Clinton 06413 203-404-7500; www.ce3inc.com 67 Clinton Contract research focused on providing biotechnology companies with phase 1 and phase 2 clinical trial execution, primarily in oncology, and regulatory submission services Private Holly Ohanesian Coulter President & CEO 2005 9 Tangen Biosciences Inc. 20 Commercial St. Branford 06405 203-433-4045; tangenbio.com 32 Branford Molecular diagnostics Private Richard C. Birkmeyer President and CEO 2013 10 Celldex Therapeutics Inc. 300 George St., Suite 530 New Haven 06511 203-483-3500; celldex.com 25 (f) Hampton, N.J. Immunotherapy, therapeutic antibodies, antibody drug conjugates, immune system modulators Public NASDAQ:CLDX Anthony Marucci President & CEO 2005 11 BioXcel Therapeutics 555 Long Wharf Drive New Haven 06511 475-238-6837; bioxceltherapeutics.com 24 (g) New Haven Biopharmaceutical firm using artificial intelligence to advance development of medicines for neuroscience, immuno-oncology and other diseases Public NASDAQ: BTAI Vimal D. Mehta Founder & CEO 2017 12 CooperSurgical Inc. (h) 95 Corporate Dr. Trumbull 06611 203-601-5200; www.coopersurgical.com 20 (i) Trumbull Development and commercialization of medical devices and diagnostics for women's health Public NYSE: COO Robert Auerbach President 1990 12 Cybrexa Therapeutics 5 Science Park, 395 Winchester Ave. New Haven 06511 860-717-2731; cybrexa.com 20 New Haven Development of therapies using Alphalex platform to deliver anti-cancer agents directly into tumor cells Private Per Hellsund President & CEO 2017 12 Kleo Pharmaceuticals Inc. 25 Science Park, Suite 235 New Haven 06511 203-691-6361; www.kleopharmaceuticals.com 20 New Haven Creation of fully synthetic compounds that recruit the immune system to destroy cancer cells Private Douglas Manion CEO 2015 12 New England Discovery Partners (j) 23 Business Park Drive Branford 06405 203-208-2523; nedp.com 20 (i) Branford Contract research in synthetic and medicinal chemistry; drug discovery services to academic, pharmaceutical and biotechnology companies Private Michael Van Zandt President & CEO 2012 16 NanoViricides Inc. 1 Controls Drive Shelton 06484 203-937-6137; nanoviricides.com 17 (k) Shelton Developer of nanomedicine drugs against viruses Public NYSE: NNVC Anil R. Diwan President & chairman 2005 16 Trevi Therapeutics 195 Church St. New Haven 06510 203-304-2499; www.trevitherapeutics.com 17 (g) New Haven Developer of nalbuphine ER to treat serious neurologically mediated conditions by targeting the central and peripheral nervous systems Public NASDAQ: TRVI Jennifer L. Good Co-founder, president & CEO 2011 18 Rallybio 234 Church St., Suite 1020 New Haven 06510 203-859-3820; rallybio.com 16 New Haven Developer of life-transforming therapies for patients with severe and rare disorders Private Martin Mackay co-founder & CEO 2018 19 Convexity Scientific Inc. (l) 418 Meadow St. Fairfield 06824 203-557-6254; convexityscientific.com 10 Fairfield (m) Developer of wearable health technology, software and hardware Private Geoff Matous President N/A 19 Synovel Laboratory LLC 375 Morgan Lane, Unit 204B West Haven 06516 203-545-9462; synovellab.com 10 West Haven Medicinal and process chemistry support for biotech and pharmaceuticals companies, university and nonprofit organizations Private Ho-Yin Lo President & CEO 2014 Sources: Each company via survey, website and/or press releases, annual 10-K reports to SEC and Labor Market Information database, Conn. Dept of Labor. Notes: N/A = not available or not applicable. (a) On Jan. 28, 2020, acquired Achillion Pharmaceuticals, previously headquarterd in Blue Bell, Penn., for $930 million. In November, 2019, Achillion reported 45 employees in New Haven. (b) With an additional R&D operation in Branford. (c) Number of employees in Conn. is 500-999 according to CT Dept. of Labor, Labor Market Information. (d) Succeeded Robert Friel upon his retirement, December 2019. (e) For parent company Sanofi S.A. based in Paris, France. (f) Data from 2018. (g) As of December 31, 2019, as reported to SEC, form 10-K. (h) A wholly owned subsidiary of The Cooper Companies. (i) Number of employees in Conn. is 20-49, according to CT Dept. of Labor, Labor Market Information. (j) In November 2019, acquired by N.J.-based Genesis Drug Discovery & Development (GD3), a member of Genesis Biotechnology Group. (k) As of August 15, 2019, as reported to SEC 10-K form; includes employees at West Haven's TheraCour Pharma Inc., to which Nanoviricies has broad, exclusive licenses. (l) Acquired New Haven-based Wellinks Inc. on Jan. 6, 2020. (m) Plans to relocate to New Haven. —Compiled by Heide Martin. Sources: Each company via survey, website and/ or press releases, annual 10-K reports to SEC and Labor Market Information database, Conn. Dept of Labor. Notes: N/A = not available or not applicable. (a) On Jan. 28, 2020, acquired Achillion Pharmaceuticals, previously headquarterd in Blue Bell, Penn., for $930 million. In November, 2019, Achillion reported 45 employees in New Haven. (b) With an additional R&D operation in Branford. (c) Number of employees in Conn. is 500-999 according to CT Dept. of Labor, Labor Market Information. (d) Succeeded Robert Friel upon his retirement, December 2019. (e) For parent company Sanofi S.A. based in Paris, France. (f) Data from 2018. (g) As of December 31, 2019, as reported to SEC, form 10-K. (h) A wholly owned subsidiary of The Cooper Companies. (i) Number of employees in Conn. is 20-49, according to CT Dept. of Labor, Labor Market Information. (j) In November 2019, acquired by N.J.-based Genesis Drug Discovery & Development (GD3), a member of Genesis Biotechnology Group. (k) As of August 15, 2019, as reported to SEC 10-K form; includes employees at West Haven's TheraCour Pharma Inc., to which Nanoviricies has broad, exclusive licenses. (l) Acquired New Haven-based Wellinks Inc. on Jan. 6, 2020. (m) Plans to relocate to New Haven. —Compiled by Heide Martin.